FOLH1 and prostate carcinoma: The ongoing EMPIRE-2 study (clinicaltrials.gov registration: NCT03762759, accessed on 31 October 2023) seeks to perform a randomized comparison of PSMA with fluciclovine with oncologic endpoints, and an ongoing FDA initiative to study “the impact of novel PET imaging tracers on real-world outcomes for patients with prostate cancer” will hopefully provide further insight [34,79].